Pharmaceuticals
SCG Cell Therapy Presented New Preclinical Data in an Oral Presentation at ASGCT 2024 Annual Meeting Highlighting Superior Tumor Inhibition of its Immunoswitch Armored HPV-TCR T Cell Therapy (SCG142) against a Broad Range of HPV-associated Cancers
SINGAPORE, May 13, 2024 /PRNewswire/ -- SCG Cell Therapy Pte Ltd (SCG), a clinical-stage biotechnology company developing novel immunotherapies for infectious diseases and their associated cancers, announced first preclinical data of its novel human papillomavirus (HPV)-specific T cell receptor-...
2024-05-13 10:00
4315
RemeGen Celebrates World Lupus Day 2024 with Increased Lupus Visibility through Vital Knowledge Sharing
The biotech company continues to offer hope to systemic lupus erythematosus (
SLE) patients globally by sharing the latest developments of its proprietary
novel fusion protein drug Telitacicept
YANTAI, China, May 10, 2024 /PRNewswire/ -- RemeGen Co. Ltd.
2024-05-10 16:26
3828
Infinitopes' Article in Peer-Reviewed Journal Seeks to Unlock the Potential of Cancer Vaccines
Publication in Human Vaccines and Immunotherapeutics highlights progress in understanding tumour biology and vaccine technologies since the pandemic OXFORD, England, May 9, 2024 /PRNewswire/ -- Infinitopes Precision Immunomics, an integrated cancer biotech combining world leading platforms in pr...
2024-05-09 15:30
3170
Approximately USD 10.8 Million Invested in New Drug Development for Malaria and NTDs in Partners Including Japanese Pharma Shionogi, Mitsubishi Tanabe, and Eisai and Europe-Based Institutions
TOKYO, May 9, 2024 /PRNewswire/ -- The Global Health Innovative Technology (GHIT) Fund announced today a total investment of approximatelyJPY 1.64 billion (USD 10.8 million1) in four projects for the development of new drugs for malaria and neglected tropical diseases (NTDs).2 The GHIT Fund inv...
2024-05-09 10:00
2800
Head-to-head Superiority to High-dose Dulaglutide: Innovent's First Phase 3 Clinical Trial of Mazdutide in Chinese Patients with Type 2 Diabetes Met Study Endpoints
SAN FRANCISCO and SUZHOU, China, May 9, 2024 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, o...
2024-05-09 08:00
4190
TraceLink Named to 2024 RXinsider Pharmacy500 List
BOSTON, May 9, 2024 /PRNewswire/ -- TraceLink, a leader in end-to-end digital supply chain solutions, is proud to announce its inclusion in the Pharmacy500 list for 2024 by RXinsider. This recognition places TraceLink among the most impactful pharmacy supply chain companies inthe United States, a...
2024-05-09 00:53
2323
Waters ACQUITY QDa II Mass Detector Delivers Wider Range of Chemical Analysis within Cost-Effective, Lower Energy Instrument
News Summary: * ACQUITY™ QDa™ II Mass Detector enhances confidence in routine compound identification using the specificity of mass analysis to boost efficiency, robustness, and productivity in LC-UV separations, while leveraging the Empower™ Chromatography Data System for complete traceabilit...
2024-05-08 20:40
2777
Everest Medicines Announces New Drug Application Approval of VELSIPITY® for Adults with Moderately to Severely Active Ulcerative Colitis in Macau
SHANGHAI, May 8, 2024 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, development, manufacturing and commercialization of innovative medicines and vaccines, announced today that the Pharmaceutical Administration ...
2024-05-08 08:05
4434
YS Biopharma to Hold Extraordinary General Meeting on May 21, 2024 and Announces the Appointment of Interim Chief Executive Officer
GAITHERSBURG, Md., May 8, 2024 /PRNewswire/ -- YS Biopharma Co., Ltd. (Nasdaq: YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious disease...
2024-05-08 04:20
3449
Sciwind Biosciences and HK inno.N Corporation Announce Licensing and Partnership Agreement for Ecnoglutide Injection (XW003) in South Korea
HANGZHOU, China and SEOUL, South Korea, May 7, 2024 /PRNewswire/ -- Sciwind Biosciences Co., Ltd., a clinical stage biopharmaceutical company focused on developing treatments for metabolic disease, and HK inno.N Corporation, a South Korean commercial stage pharmaceutical company (KOSDAQ: 195940),...
2024-05-07 15:00
4053
Innovent Receives NMPA Breakthrough Therapy Designation for IBI343（Anti-Claudin18.2 ADC）as Monotherapy for Advanced Gastric Cancer
SAN FRANCISCO and SUZHOU, China, May 7, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ...
2024-05-07 08:12
4198
Alphamab Oncology to Present Chinese Clinical Data of JSKN003 for the Treatment of HER2-expressing Solid Tumors for the First Time at the 2024 ASCO Annual Meeting
SUZHOU, China, May 6, 2024 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that data from the clinical study conducted inChina (JSKN003-102) of anti-HER2 bispecific antibody-drug conjugate (ADC) JSKN003 for the treatment of HER2-expressing advanced solid tumors, will be presente...
2024-05-06 10:25
3540
VYNDAMAX® (tafamidis) PBS-listed for adult patients with wild-type or hereditary transthyretin amyloid cardiomyopathy (ATTR-CM) with New York Heart Association (NYHA) Class I-II heart failure
* VYNDAMAX has been listed on the Pharmaceutical Benefits Scheme (PBS) for adult patients with wild-type or hereditary transthyretin amyloid cardiomyopathy (ATTR-CM)with New York Heart Association (NYHA) Class I-II heart failure.[1] * ATTR-CM is a debilitating and often fatal condition that l...
2024-05-04 18:00
3653
Everest Medicines Announces Hong Kong Department of Health Approval of Nefecon® for the Treatment for Primary IgA Nephropathy in Adult Patients
SHANGHAI, May 2, 2024 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company") announced that the Hong Kong Department of Health had approved Nefecon® for the treatment of primary immunoglobulin A nephropathy (IgAN) in adults at risk of disease progression.Hong Kong marks the...
2024-05-02 09:23
4805
3Shape Unveils Unite 3rd Generation: Access TRIOS Scans Anywhere, Anytime
COPENHAGEN, Denmark, May 1, 2024 /PRNewswire/ -- 3Shape launches Unite 3rd Generation, allowing dental professionals to access and work with their digital impressions and patient cases anywhere, anytime, via any mobile, tablet (Android, iOS), or web device. This update enables seamless and secure...
2024-05-01 21:43
2816
ArisGlobal Helps Boehringer Ingelheim Transform Safety Signal Processing by Leveraging Latest LifeSphere Solutions
LifeSphere Clarity drives efficiencies and reinvents the way Boehringer Ingelheim's pharmaceutical operations approach safety signals BOSTON, May 1, 2024 /PRNewswire/ -- ArisGlobal, a market leader in Life Sciences technology and the creator of LifeSphere®, announced today that research-driven g...
2024-05-01 20:00
3234
Medison Pharma and Alnylam Pharmaceuticals Announce Expansion of their Multi-Regional Partnership in Europe and Israel to Commercialize RNAi Therapeutics in additional LATAM and APAC markets including Australia
* The expanded partnership will allow Alnylam and Medison to help accelerate access for patients in multiple regions under one global alliance * Medison, the creator and leader of the multi-regional partnership category, will utilize its unique, unifiedplatform for efficient global commerciali...
2024-04-30 19:00
4365
Innovent Announces the Appointment of Dr. Samuel Zhang as Global Chief Business Officer (CBO)
SAN FRANCISCO and SUZHOU, China, April 30, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, cardiovascular and metabolic, autoimmune,...
2024-04-30 12:30
4821
Chang Gung Memorial Hospital, Linkou, Garners Two Prestigious International Awards for Its Outstanding Achievements
The hospital honored with Hospital of the Year - Taiwan and Smart Hospital Initiative of the Year -Taiwan at the Healthcare Asia Awards TAOYUAN, April 30, 2024 /PRNewswire/ -- The Healthcare Asia Awards, a prestigious international recognition program, honors exceptional healthcare institutions ...
2024-04-30 09:03
4067
Henlius Trastuzumab Receives FDA Approval in the United States
SHANGHAI, April 29, 2024 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK) announced that the company's business partner, Accord BioPharma Inc. (the U.S. specialty division of Intas Pharmaceuticals, Ltd.), has received approval from the United States Food and Drug Administration (FDA) for ...
2024-04-29 20:18
4712
Week's Top Stories
Most Reposted
Visa returns as title sponsor for 2026 MAMA AWARDS; Visa Presale registration begins 13 October
[Picked up by 310 media titles]
2026-10-13 10:00
Agoda and Emerging Travel Group Enter Strategic Partnership
[Picked up by 292 media titles]
2026-10-15 16:00Food & Hospitality Asia 2027 Redefining Excellence: The Premier Platform for Food & Beverage and Hospitality Innovation
[Picked up by 281 media titles]
2026-10-15 10:00Leading Asian DMC Discova to Attend ITB Asia 2026
[Picked up by 280 media titles]
2026-10-15 12:59
DayOne Upsizes Malaysia Financing to US$7.2 Billion; Total Billings Surpass 1GW and Bookings Reach 2.3GW
[Picked up by 270 media titles]
2026-10-14 18:01Most Read
Sonilo Raises $11M to Build the AI-Native Audio Stack for Video
2026-10-15 00:00
19798
Visa returns as title sponsor for 2026 MAMA AWARDS; Visa Presale registration begins 13 October
2026-10-13 10:00
17556
Agoda and Emerging Travel Group Enter Strategic Partnership
2026-10-15 16:00
7917